PMID- 33813814
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 45
IP  - 2
DP  - 2021 Mar
TI  - Diabetes Management in Patients with Heart Failure.
PG  - 158-172
LID - 10.4093/dmj.2020.0296 [doi]
AB  - Diabetes and heart failure (HF) are common diseases, each affecting large 
      segments of the world population. Moreover, prevalence rates for both are 
      expected to rise dramatically over coming decades. The high prevalence rates of 
      both diseases and wellrecognized association of diabetes as a risk factor for HF 
      make it inevitable that both diseases co-exist in a large number of patients, 
      complicating their management and increasing the risk of a poor outcome. 
      Management of diabetes has been shown to impact clinical events in patients with 
      HF and there is emerging evidence that agents used to treat diabetes can reduce 
      HF events, even in non-diabetic patients. In this review we summarize the 
      clinical course and treatment of patients with type 2 diabetes mellitus (T2DM) 
      and HF and review the efficacy and safety of pharmacological agents in patients 
      with T2DM at risk for HF and those with established disease.
FAU - Shen, Jia
AU  - Shen J
AD  - Division of Cardiology, Department of Medicine, University of California San 
      Diego, La Jolla, CA, USA.
FAU - Greenberg, Barry H
AU  - Greenberg BH
AD  - Division of Cardiology, Department of Medicine, University of California San 
      Diego, La Jolla, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210325
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Heart Failure/epidemiology/therapy
MH  - Humans
MH  - Prevalence
MH  - Risk Factors
MH  - *Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC8024151
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Heart failure
OT  - Risk factors
OT  - Sodium glucose cotransporter 2 inhibitor
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/04/06 06:00
MHDA- 2021/10/16 06:00
PMCR- 2021/03/01
CRDT- 2021/04/05 03:18
PHST- 2020/12/15 00:00 [received]
PHST- 2021/02/25 00:00 [accepted]
PHST- 2021/04/05 03:18 [entrez]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/03/01 00:00 [pmc-release]
AID - dmj.2020.0296 [pii]
AID - dmj-2020-0296 [pii]
AID - 10.4093/dmj.2020.0296 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2021 Mar;45(2):158-172. doi: 10.4093/dmj.2020.0296. Epub 2021 
      Mar 25.